Xencor, Vir Biotechnology collaborate on Xtend XmAb antibody technology for COVID-19

This article was originally published here

Under the deal, Vir can non-exclusively access Xencor’s Xtend Fc technology to expand the half-life of novel antibodies, which are being assessed as potential treatments for patients with

The post Xencor, Vir Biotechnology collaborate on Xtend XmAb antibody technology for COVID-19 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply